Display options
Cite
Wennmann M, Kintzelé L, Piraud M, et al. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget. 2018;9(38):25254-25264doi: 10.18632/oncotarget.25402.
Wennmann, M., Kintzelé, L., Piraud, M., Menze, B. H., Hielscher, T., Hofmanninger, J., Wagner, B., Kauczor, H. U., Merz, M., Hillengass, J., Langs, G., & Weber, M. A. (2018). Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget, 9(38), 25254-25264. https://doi.org/10.18632/oncotarget.25402
Wennmann, Markus, et al. "Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients." Oncotarget vol. 9,38 (2018): 25254-25264. doi: https://doi.org/10.18632/oncotarget.25402
Wennmann M, Kintzelé L, Piraud M, Menze BH, Hielscher T, Hofmanninger J, Wagner B, Kauczor HU, Merz M, Hillengass J, Langs G, Weber MA. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget. 2018 May 18;9(38):25254-25264. doi: 10.18632/oncotarget.25402. eCollection 2018 May 18. PMID: 29861868; PMCID: PMC5982766.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 May 18;9(38):25254-25264. doi: 10.18632/oncotarget.25402. eCollection 2018 May 18.

Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.

Oncotarget

Markus Wennmann, Laurent Kintzelé, Marie Piraud, Bjoern H Menze, Thomas Hielscher, Johannes Hofmanninger, Barbara Wagner, Hans-Ulrich Kauczor, Maximilian Merz, Jens Hillengass, Georg Langs, Marc-André Weber

Affiliations

  1. Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
  2. Department of Computer Science, Technical University of Munich, Munich, Germany.
  3. Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  4. Department of Biomedical Imaging and Image-Guided Therapy, Computational Imaging Research Laboratory, Medical University of Vienna, Vienna, Austria.
  5. Department of Medicine V, Multiple Myeloma Section, University of Heidelberg, Heidelberg, Germany.
  6. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  7. Institute of Diagnostic and Interventional Radiology, University Medical Center Rostock, Rostock, Germany.

PMID: 29861868 PMCID: PMC5982766 DOI: 10.18632/oncotarget.25402

Abstract

The purpose of this study was to improve risk stratification of smoldering multiple myeloma patients, introducing new 3D-volumetry based imaging biomarkers derived from whole-body MRI. Two-hundred twenty whole-body MRIs from 63 patients with smoldering multiple myeloma were retrospectively analyzed and all focal lesions >5mm were manually segmented for volume quantification. The imaging biomarkers total tumor volume, speed of growth (development of the total tumor volume over time), number of focal lesions, development of the number of focal lesions over time and the recent imaging biomarker '>1 focal lesion' of the International Myeloma Working Group were compared, taking 2-year progression rate, sensitivity and false positive rate into account. Speed of growth, using a cutoff of 114mm

Keywords: biomarker; risk stratification; smoldering multiple myeloma; speed of growth; volumetry

Conflict of interest statement

CONFLICTS OF INTEREST Outside the submitted work the following relationships are reported: J.Hi.: Consultancy: Amgen, Celgene; Honoraria: Amgen, BMS, Celgene, Janssen, Novartis, Takeda; Research Fundi

References

  1. Br J Haematol. 2003 Jun;121(5):749-57 - PubMed
  2. Radiologe. 2018 Jan;58(1):72-78 - PubMed
  3. Sci Rep. 2016 Apr 27;6:25007 - PubMed
  4. Int J Cancer. 2014 Nov 15;135(10):2380-6 - PubMed
  5. J Clin Oncol. 2010 Mar 20;28(9):1606-10 - PubMed
  6. Lancet Oncol. 2016 Aug;17 (8):1127-1136 - PubMed
  7. N Engl J Med. 2011 Aug 4;365(5):474-5 - PubMed
  8. Blood Cancer J. 2016 Jul 29;6(7):e454 - PubMed
  9. Leukemia. 2014 Dec;28(12):2402-3 - PubMed
  10. Neuroimage. 2006 Jul 1;31(3):1116-28 - PubMed
  11. Br J Haematol. 2011 Jun;153(6):721-8 - PubMed
  12. Br J Haematol. 2003 Nov;123(4):631-6 - PubMed
  13. N Engl J Med. 2009 Dec 3;361(23 ):2221-9 - PubMed
  14. Leukemia. 2014 Sep;28(9):1902-8 - PubMed
  15. Br J Haematol. 2016 Jul;174(1):127-35 - PubMed
  16. Br J Haematol. 1999 Mar;104(4):723-9 - PubMed
  17. Nat Commun. 2017 Aug 16;8(1):268 - PubMed
  18. N Engl J Med. 2007 Jun 21;356(25):2582-90 - PubMed
  19. J Clin Oncol. 1995 Jan;13(1):251-6 - PubMed
  20. Radiology. 2010 Oct;257(1):195-204 - PubMed
  21. Leukemia. 2013 Apr;27(4):941-6 - PubMed
  22. Blood. 2014 Jan 2;123(1):78-85 - PubMed
  23. Thorax. 2012 Apr;67(4):296-301 - PubMed
  24. Leukemia. 2016 Feb;30(2):417-22 - PubMed
  25. Lancet Oncol. 2014 Nov;15(12):e538-48 - PubMed
  26. Biometrics. 2000 Jun;56(2):337-44 - PubMed
  27. Clin Radiol. 2014 Aug;69(8):841-8 - PubMed

Publication Types